Sutro Biopharma (STRO) Stock Price, News & Analysis

Company Overview

Sutro Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas.

With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.

Key Stats

• Today's Range: $36.31 to $39.74
• 50-Day Range: $18.40 to $36.62
• 52-Week Range: $6.74 to $39.74
• Volume: 236,767 shs
• Average Volume: 184,068 shs
• Market Capitalization: $618.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.78
• Consensus Rating: Moderate Buy

Sutro Biopharma Stock Analysis - MarketRank™

Sutro Biopharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 429th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sutro Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.

Upside/Downside

The consensus price target for Sutro Biopharma is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Sutro Biopharma has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sutro Biopharma are expected to grow in the coming year, from ($9.17) to ($8.28) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sutro Biopharma is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sutro Biopharma is -1.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.69% of the float of Sutro Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Sutro Biopharma has a short interest ratio ("days to cover") of 2.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sutro Biopharma has recently increased by 17.04%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sutro Biopharma does not currently pay a dividend.

Dividend Growth

Sutro Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.85

News Sentiment

Sutro Biopharma has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 26 news articles for Sutro Biopharma this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sutro Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.60% of the stock of Sutro Biopharma is held by insiders.

Percentage Held by Institutions

96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STRO Stock Analysis - Frequently Asked Questions

How have STRO shares performed this year?

Sutro Biopharma's stock was trading at $11.57 at the beginning of 2026. Since then, STRO stock has increased by 222.9% and is now trading at $37.36.

How were Sutro Biopharma's earnings last quarter?

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings data on Thursday, November, 6th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.25. The company had revenue of $9.69 million for the quarter, compared to analysts' expectations of $10.14 million.

When did Sutro Biopharma's stock split?

Sutro Biopharma's stock reverse split on Wednesday, December 3rd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 2nd 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Sutro Biopharma IPO?

Sutro Biopharma (STRO) raised $85 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,667,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Sutro Biopharma's major shareholders?

Top institutional shareholders of Sutro Biopharma include Sigma Planning Corp (0.08%). Insiders that own company stock include Jane Chung, Hans-Peter Gerber, David Pauling, Connie Matsui, Gregory K Chow, Nicki Vasquez and Brunilda Shtylla.
View institutional ownership trends.

How do I buy shares of Sutro Biopharma?

Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Sutro Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sutro Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Moderna (MRNA) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/06/2025
• Today: 5/05/2026
• Next Earnings (Estimated): 5/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:STRO
• CIK: 1382101
• Web: www.sutrobio.com
• Phone: (650) 392-8412
• Fax: N/A
• Employees: 240
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Sutro Biopharma: $40.78
• High Price Target: $100.00
• Low Price Target: $8.00
• Potential Upside/Downside: +9.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.85
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($26.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$191.09 million
• Net Margins: -186.45%
• Pretax Margin: -186.54%
• Return on Equity: N/A
• Return on Assets: -79.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.01
• Quick Ratio: 2.01

Sales & Book Value

• Annual Sales: $102.48 million
• Price / Sales: 6.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($15.43) per share
• Price / Book: -2.42

Miscellaneous

• Outstanding Shares: 16,568,000
• Free Float: 15,590,000
• Market Cap: $618.32 million
• Optionable: Optionable
• Beta: 1.63